Extended Adjuvant Therapy for Breast Cancer—How Much Is Enough?

Jakesz et al have reported mature results of another extended adjuvant therapy trial, ABCSG Trial 6a, a randomized open-label trial that enrolled 856 postmenopausal women from ABCSG Trial 6. An editorial suggests that the ABCSG Trial 6a has some important limitations.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JNCI : Journal of the National Cancer Institute 2007-12, Vol.99 (24), p.1825-1827
Hauptverfasser:	Prowell, Tatiana M., Stearns, Vered
Format:	Artikel
Sprache:	eng
Schlagworte:	Aminoglutethimide - therapeutic use Antineoplastic Agents, Hormonal - adverse effects Antineoplastic Agents, Hormonal - therapeutic use Aromatase Inhibitors - adverse effects Aromatase Inhibitors - therapeutic use Austria Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - prevention & control Chemotherapy, Adjuvant Clinical trials Disease-Free Survival Drug therapy Female Humans Nitriles - adverse effects Nitriles - therapeutic use Oncology Postmenopause Randomized Controlled Trials as Topic Tamoxifen - therapeutic use Treatment Outcome Triazoles - adverse effects Triazoles - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Jakesz et al have reported mature results of another extended adjuvant therapy trial, ABCSG Trial 6a, a randomized open-label trial that enrolled 856 postmenopausal women from ABCSG Trial 6. An editorial suggests that the ABCSG Trial 6a has some important limitations.
ISSN:	0027-8874 1460-2105
DOI:	10.1093/jnci/djm264